Dec 6 Biohaven Pharmaceutical said on
Friday it would continue testing its Alzheimer's disease
treatment in a late-stage study as the drug had passed a
so-called "futility analysis", sending shares up 4.1%.
The U.S. FDA denied Lexicon Pharmaceuticals Inc's appeal against the rejection of its add-on treatment for type 1 diabetes, marking the company's third major setback this year and sending its shares plunging 18% on Monday.
Nov 25 The U.S. Food and Drug Administration
said on Monday it approved a drug from Global Blood Therapeutics
Inc to treat sickle cell disease in adults and children
12 years or older.
Alnylam Pharmaceuticals Inc priced its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain at $575,000 per year after receiving an early U.S. approval on Wednesday.
A panel of experts to the U.S. FDA recommended allowing Amarin Corp Plc's fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.
Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.
SmileDirectClub Inc , in its first results since going public in September, reported a bigger quarterly loss on Tuesday as expenses rose and the teeth alignment company pointed toward more losses for the year.
Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc said.
Drugmaker Regeneron Pharmaceuticals Inc beat analysts' estimates for third-quarter profit on Tuesday, boosted by higher demand for its blockbuster eye drug, Eylea, and eczema therapy Dupixent.